Drug Combination Shows Promising Long-Term Survival in Advanced Thymic Cancer
Audio narration · Coming soon
Final results from the phase 2 PECATI clinical trial reveal encouraging long-term survival outcomes using a combination of lenvatinib and pembrolizumab in patients with previously treated advanced B3-thymoma and thymic carcinoma. This announcement marks a significant development in treatment options for these rare and aggressive cancers.
Originally published by gnews